ELIO CACCIOLA, M.D.; ROSARIO GLUSTOLISI, M.D.
To the editor: Barton and Conrad reported in the February 1979 issue (1) that post-transfusion hepatitis developing in patients with acute myelogenous leukemia may improve the prognosis. They had found a longer survival after chemotherapy (mean 76.9 weeks) in a "hepatitic" group than in a "non-hepatitic" group (mean 39.6 weeks). They postulated that beneficial effects of hepatitis in patients with acute myelogenous leukemia could reflect a greater immunocompetence. Subsequently, Rosner (2) suggested three additional hypotheses: hepatic patients might be more sensitive to antileukemic drugs because of a lack of cytarabine deaminase; the hepatitis virus might potentiate entry of antileukemic drugs
CACCIOLA E, GLUSTOLISI R. Acute Myelogenous Leukemia and Hepatitis. Ann Intern Med. ;92:127–128. doi: 10.7326/0003-4819-92-1-127
Download citation file:
Published: Ann Intern Med. 1980;92(1):127-128.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use